Vasculitis and the NLRP3 inflammasome.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
medline:
29
11
2023
pubmed:
15
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
Vasculitis are a group of heterogeneous conditions characterized by chronic inflammation of blood vessels, leading to tissue destruction and organ failure. Vasculitis is an inflammatory process in which immune effector cells infiltrate blood vessels and surrounding tissues. The involvement of inflammasomes seems to occur during inflammatory processes. Studies have emphasized that genetic susceptibility is an important aspect of the pathogenesis of vasculitis. The innate immune system is a major contributor to these inflammatory diseases, suggesting that the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome plays a key role. NLRP3 activation causes the assembly of a large multiprotein and leads to the secretion of bioactive interleukin (IL)-1β and IL-18 as well as the induction of inflammatory cell death, termed pyroptosis. Accumulating evidence confirms the involvement of this cascade in sterile inflammatory diseases and other vascular diseases. In this review, we will summarize the current state of knowledge regarding the role of NLRP3 inflammasome in vascular diseases, and discuss the potential of the NLRP3 inflammasome as a therapeutic target.
Identifiants
pubmed: 37582052
doi: 10.1097/BOR.0000000000000962
pii: 00002281-990000000-00072
doi:
Substances chimiques
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Interleukin-1beta
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-15Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hatemi G, Esatoglu SN, Yazici Y. Biomarkers in vasculitis. Curr Opin Rheumatol 2018; 30:30–35.
Silva-Fernández L, Loza E, et al. Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum 2014; 43:542–557.
Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol 2016; 67:1738–1749.
Okazaki T, Shinagawa S, Mikage H. Vasculitis syndromediagnosis and therapy. J Gen Fam Med 2017; 18:72–78.
Hara T, Yamamura K, Sakai Y. The up-to-date pathophysiology of Kawasaki disease. Clin Transl Immunol 2021; 10:e1284.
Hayward JA, Mathur A, Ngo C, Man SM. Cytosolic recognition of microbes and pathogens: inflammasomes in action. Microbiol Mol Biol Rev 2018; 82:e00015–e18.
Jia C, Zhang J, Chen H, et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis 2019; 10:778.
Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J 2014; 55:101–105.
Kelley N, Jeltema D, Duan YH, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 2019; 20:3328.
Kuida K, Lippke JA, Ku G, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995; 267:2000–2003.
Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res 2018; 122:1722–1740.
Abbate A, Toldo S, Marchetti C, et al. Interleukin- 1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res 2020; 126:1260–1280.
Jin Y, Fu J. Novel insights into the NLRP3 inflammasome in atherosclerosis. JAH 2019; 8:e012219.
Mangan MSJ, Olhava EJ, Roush WR, et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 2018; 17:688.
Takahashi M. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res 2022; 118:372–385.
Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 2016; 16:407–420.
Shin JI, Lee KH, Joo YH, et al. Inflammasomes and autoimmune and rheumatic diseases: a comprehensive review. J Autoimmun 2019; 103:102299.
Malik A, Kanneganti TD. Inflammasome activation and assembly at a glance. J Cell Sci 2017; 130:3955–3963.
Sharma D, Kanneganti TD. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol 2016; 213:617–629.
Takahashi M, Ikeda U, Masnama J-I, et al. Involvement of adhesion molecules in human monocyte adhesion to and transmigration through endothelial cells in vitro. Atherosclerosis 1994; 108:73–81.
Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 2017; 70:2278–2289.
Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81:487–498.
Gerdes N, Sukhova GK, Libby P, et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 1 95:245–257.
Akbal A, Dernst A, Lovotti M, et al. How location and cellular signaling combine to activate the NLRP3 inflammasome. Cell Mol Immunol 2022; 19:1201–1214.
Zhang W, Li Z, Yang H, et al. Aeromonas sobria induces proinflammatory cytokines production in mouse macrophages via activating NLRP3 inflammasome signaling pathways. Front Cell Infect Microbiol 2021; 11:691445.
Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci 2019;20:649; Elhage R, Ljunggren HG, Hansson GK. Proatherogenic role of interleukin-18: effects on inflammation and action on vascular cells. Cardiovasc Res 2012;96:176–180.
D’Amico R, Fusco R, Cordaro M, et al. Modulation of NLRP3 inflammasome through formyl peptide receptor 1 (Fpr-1) pathway as a new therapeutic target in bronchiolitis obliterans syndrome. Int J Mol Sci 2020; 21:2144.
Fusco R, D’amico R, Cordaro M, et al. Absence of formyl peptide receptor 1 causes endometriotic lesion regression in a mouse model of surgically-induced endometriosis. Oncotarget 2018; 9:31355.
Fusco R, Gugliandolo E, Biundo F, et al. Inhibition of inflammasome activation improves lung acute injury induced by carrageenan in a mouse model of pleurisy. FASEB J 2017; 31:3497–3511.
Guo W, Liu W, Jin B, Geng J, et al. Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation. Int Immunopharmacol 2015; 24:232–238.
Shahi A, Afzali S, Firoozi Z, et al. Potential roles of NLRP3 inflammasome in the pathogenesis of Kawasaki disease. J Cell Physiol 2023; 238:513–532.
Tamura N, Maejima Y, Matsumura T, et al. Single-nucleotide polymorphism of the MLX gene is associated with Takayasu arteritis. circulation. Genomic Precis Med 2018; 11:e002296.
Guo K, Qiu L, Xu Y, et al. Single-nucleotide polymorphism LncRNA AC008392.1/rs7248320 in CARD8 is associated with Kawasaki disease susceptibility in the Han Chinese population. J Inflamm Res 2021; 14:4809–4816.
Padula MC, Leccese P, Lascaro N, et al. Identification of a de novo NLRP3 gene variation in an Italian Behçet syndrome patient. Int J Immunogenet 2019; 46:339–341.
Efthimiou P, Petryna O, Nakasato P, Kontzias A. New insights on multigenic autoinflammatory diseases. Ther Adv Musculoskelet Dis 2022; 14:1759720X221117880.
Vitale A, Rigante D, Lopalco G, et al. Interleukin-1 inhibition in Behçet's disease. The Israel Medical Assoc J 2016; 18:171–176.
Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31:205–210.
Sadeghi A, Davatchi F, Shahram F, et al. Serum profiles of cytokines in Behcet's disease. J Clin Med 2017; 6:49.
Gholijani N, Ataollahi MR, Samiei A, et al. An elevated pro-inflammatory cytokines profile in Behcet's disease: a multiplex analysis. Immunol Lett 2017; 186:46–51.
Liang L, Tan X, Zhou Q, et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behçet's disease. Invest Ophthalmol Vis Sci 2013; 54:402–414.
Hatemi G, Fresko I, Tascilar K, Yazici H. Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 2008; 58:1539.
Yüksel Ş, Eren E, Hatemi G, et al. Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients. Int Immunol 2014; 26:71–81.
Jamilloux Y, Lefeuvre L, Magnotti F, et al. Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. Rheumatology (Oxford) 2018; 57:100–111.
Kirino Y, Zhou Q, Ishigatsubo Y, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci USA 2013; 110:8134.
Serarslan G, Cura SE, Kimyon G, et al. Association of MEFV mutations and vascular involvement in Behçet's disease: a study from Hatay, Turkey. Reumatologia 2022; 60:220–223.
Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 2006; 13:236.
Kim EH, Park MJ, Park S, Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease. J Inflamm (Lond) 2015; 1 2:41.
Novak T, Hamedi M, Bergmeier LA, et al. Saliva and serum cytokine profiles during oral ulceration in Behçet's disease. Front Immunol 2021; 12:724900.
Ortiz F, Acuña-Castroviejo D, Doerrier C, et al. Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis. J Pineal Res 2015; 58:34–49.
Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med 2014; 65:223–244.
Hamzaoui K, Borhani-Haghighi A, Dhifallah IB, Hamzaoui A. Elevated levels of IL-32 in cerebrospinal fluid of neuro-Behcet disease: correlation with NLRP3 inflammasome. J Neuroimmunol 2022; 365:577820.
Ugurel E, Erdag E, Kucukali CI, et al. Enhanced NLRP3 and DEFA1B expression during the active stage of parenchymal neuro-Behçet's disease. In Vivo 2019; 33:1493–1497.
Khemani C, Khubchandani R. CINCA syndrome. Indian Pediatr 2007; 44:933–936.
Russo RAG, Katsicas MM. Chronic infantile neurological cutaneous and articular syndrome: two new cases with rare manifestations. Acta Paediatr Int J Paediatr 2001; 90:1076–1079.
Dollfus H, Hafner R, Hofmann HM, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol 2000; 118:1386–1392.
Porritt RA, Zemmour D, Abe M, et al. NLRP3 inflammasome mediates immune-stromal interactions in vasculitis. Circ Res 2021; 129:e183–e200.
Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol 2015; 11:475–482.
Alphonse MP, Duong TT, Tam S, Yeung RSM. Mercury increases IL-1β and IL-18 secretion and intensifies coronary arteritis in an animal model of Kawasaki disease. Front Immunol 2023; 14:1126154.
Gao PC, Chen XW, Chu J, et al. Antagonistic effect of selenium on mercuric chloride in the central immune organs of chickens: The role of microRNA-183/135b-FOXO1/TXNIP/NLRP3 inflammasome axis. Environ Toxicol 2022; 37:1047–1057.
Lee Y, Wakita D, Dagvadorj J, et al. IL-1 signaling is critically required in stromal cells in Kawasaki disease vasculitis mouse model: role of both IL-1α and IL-1β. Arterioscler Thromb Vasc Biol 2015; 35:2605–2616.
Maruyama D, Kocatürk B, Lee Y, et al. MicroRNA-223 regulates the development of cardiovascular lesions in LCWE-induced murine Kawasaki disease vasculitis by repressing the NLRP3 inflammasome. Front Pediatr 2021; 9:662953.
Bauernfeind F, Rieger A, Schildberg FA, et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012; 189:4175–4181.
Kundu A, Maji S, Kumar S, et al. Clinical aspects and presumed etiology of multisystem inflammatory syndrome in children (MIS-C): a review. Clin Epidemiol Glob Health 2022; 14:100966.
Root-Bernstein R. From co-infections to autoimmune disease via hyperactivated innate immunity: COVID-19 autoimmune coagulopathies, autoimmune myocarditis and multisystem inflammatory syndrome in children. Int J Mol Sci 2023; 24:3001.
Wang LY, Sun XJ, Chen M, Zhao MH. The expression of NOD2, NLRP3 and NLRC5 and renal injury in antineutrophil cytoplasmic antibody-associated vasculitis. J Transl Med 2019; 17:197.
Tashiro M, Sasatomi Y, Watanabe R, et al. IL-1β promotes tubulointerstitial injury in MPO-ANCA-associated glomerulonephritis. Clin Nephrol 2016; 86:190–199.
Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21:248–255.
Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 2019; 15:556–559.
Shah F, Greene N. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space. Chem Res Toxicol 2014; 27:86–98.
Ren P, Wu D, Appel R, et al. Targeting the NLRP3 inflammasome with inhibitor MCC950 prevents aortic aneurysms and dissections in mice. J Am Heart Assoc 2020; 9:e014044.
Li Y, Niu X, Xu H, et al. VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis. Exp Cell Res 2020; 389:111847.
Keping Y, Yunfeng S, Pengzhuo X, et al. Sestrin1 inhibits oxidized low-density lipoprotein-induced activation of NLRP3 inflammasome in macrophages in a murine atherosclerosis model. Eur J Immunol 2020; 50:1154–1166.
Domiciano TP, Wakita D, Jones HD, et al. Quercetin inhibits inflammasome activation by interfering with ASC oligomerization and prevents interleukin-1 mediated mouse vasculitis. Sci Rep 2017; 7:41539.
Shatoor AS, Al Humayed S. The protective effect of Crataegus aronia against high-fat diet-induced vascular inflammation in rats entails inhibition of the NLRP-3 inflammasome pathway. Cardiovasc Toxicol 2020; 20:82–99.
Zahid A, Li B, Kombe AJK, et al. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 2019; 10:2538.
Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 2019; 10:128.
Ji ML, Dong JY, Xu Y, et al. Inositol-triphosphate 3-kinase C and DNA methylation involvement in NLRP3 inflammasome activation in Kawasaki disease. Indian J Pediatr 2023; 90:22–28.